Article

4 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Print Print
Recommend this article Recommend this article
Save as favorites Save as favorites
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Journal of the American Academy of Dermatology
Volume 68, n° 3
pages 385-394 (mars 2013)
Doi : 10.1016/j.jaad.2012.09.024
accepted : 13 September 2012
Original Articles
Detection of Ro/SS-A antibodies in lupus erythematosus: What does it mean for the dermatologist?
 

Barbara C. Böckle, MD a, ⁎ , Gunda Stanarevic, MTA a, Norbert T. Sepp, MD a, b
a Department of Dermatology, Innsbruck Medical University, Innsbruck, Austria 
b Barbara Bommer Foundation for Clinical Immundermatology, Department of Dermatology, Innsbruck Medical University, Innsbruck, Austria 

Reprint requests: Barbara C. Böckle, MD, Department of Dermatology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria.
Abstract
Background

Lupus erythematosus (LE) is a systemic autoimmune disease. However, some patients have only cutaneous LE (CLE), whereas others develop internal organ involvement. Ro/SS-A antibodies are frequently detected in photosensitive variants of LE.

Objective

The prevalence of LE-specific and LE-nonspecific cutaneous manifestations and their relation to internal organ involvement in Ro/SS-A antibody–positive patients were investigated.

Methods

All Ro/SS-A-positive patients between January 2000 and December 2011 were reviewed. Only patients with Ro/SS-A antibodies and LE were enrolled and retrospectively analyzed.

Results

In all, 215 Ro/SS-A antibody–positive patients were given the diagnosis of LE. Older patients (>50 years old) presenting with subacute CLE or chronic CLE and negative antinuclear antibody usually only experienced skin involvement. In contrast, internal organ involvement was observed in younger patients (<50 years old) with subacute CLE or chronic CLE presenting with the clinical and laboratory markers: fatigue, positive antinuclear antibody, and additional extractable nuclear antigen. Young female patients with acute CLE should be recognized as a separate subset of Ro/SS-A antibody–positive patients because almost a third was given the diagnosis of kidney involvement. Logistic regression analysis revealed that internal organ involvement was observed in patients with LE presenting with LE-nonspecific cutaneous manifestations, arthralgia, leukopenia, positive antinuclear antibody, and fatigue.

Limitations

This was a retrospective study from a single referral center specializing in dermatologic diseases.

Conclusion

The particular cutaneous variant of LE and age at Ro/SS-A detection predict different risks for internal organ involvement in Ro/SS-A antibody–positive patients with LE.

The full text of this article is available in PDF format.

Key words : internal organ involvement, lupus erythematosus, lupus erythematosus–nonspecific cutaneous manifestations, lupus erythematosus–specific cutaneous manifestations, Ro/SS-A antibody

Abbreviations used : ACLE, ANA, APS, ARA, CCLE, CHLE, CI, CLE, DLE, ENA, LE, LET, MLE, OR, SCLE, SLE, SS


OutlineMasquer le plan
Methods  (+)
Results  (+)
Discussion

 Funding sources: None.
 Conflicts of interest: None declared.



© 2012  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline